Sterling Pathology lauds decision, urges testing
LOS ANGELES—The White House last week announced that testing would be covered in its new pandemic strategy. Sterling Pathology, based in California which has confirmed Omicron cases, lauded the decision and continued its campaign urging testing.
“Sterling Pathology has been beating the drum that testing is a powerful tool and actually is a strategy out of the pandemic,” added Dr. Yang, Sterling Pathology medical director. “We are urging scalable testing and tailored programs for schools, colleges, nursing homes, large gatherings, sporting events, musical events, festivals, travel, jails and prisons. Americans need better access to testing so that we can stop the spread.”
Rapid tests can deliver results within 15 minutes and are becoming more popular because of their speed of reporting Covid-19 positive results. However, PCR tests are the “gold standard” and despite the longer 24-48 hour time window for results and can even detect results in asymptomatic cases.
The tests Sterling Pathology offers are FDA-approved for emergency use authorization (EUA) during the COVID-19 pandemic. The pathology and genomics lab offers tailored programs that allow large organizations like schools, businesses and governments to administer and oversee scalable testing.
“We need to ensure that as a society that we are not leaving anyone behind in the fight against Covid-19,” said Dr. Yang. “Testing is a crucial tool in the war for our lives, our communities, and our society.”
Sterling Pathology’s molecular testing is capable of detecting active COVID-19 infections in the human body. Unique genetic markers of the virus can be found in RNA that only remains in the body while the virus invades and replicates itself. The benefits of molecular testing is its sensitivity in detecting active infections, allowing patients to receive appropriate treatment options from their Care Provider, and take measures to prevent spreading the infections.
